![](https://investorshub.advfn.com/uicon/564105.png?cb=1547105359)
Wednesday, November 08, 2017 10:52:47 AM
Even if someone at Colombia or Strasbourg was recommending design changes, that shouldn't negatively impact the schedule. Any additional engineering required would be going on in the background while the trials continue. If there was anything that critically wrong, it would have been picked up by now at Nicholson. And the schedule already has additional engineering built into it; part of the purpose of clinical trials is to determine if any final design tweaks are desired (and evaluate if they are worth implementing at this juncture). Based upon early feedback from Nicholson, it would appear to me they likely have a marketable design and have a strong chance of coming to market earlier than planned due to no additional design efforts being required.
FEATURED ELEMENT79 GOLD CORP PROVIDES UPDATE ON CHACHAS COMMUNITY CHARTER AND REVENUE GENERATION, M&A ACTIVITIES • Jul 30, 2024 8:00 AM
Avant Technologies Opens Equity Line with GHS Investments as Company Explores Expansion into Additional Technologies • AVAI • Jul 30, 2024 8:00 AM
INDEXR AI Merges With Moon Equity Holdings Corp. (MONI), Creating a Leading-edge Technology Company • MONI • Jul 29, 2024 9:59 AM
Cannabix Technologies to Deliver Innovative Breath Logix Alcohol Screening Device to Texas, USA • BLOZF • Jul 29, 2024 9:07 AM
BNCM AND DELEX UNVEIL POST-MERGER MANAGEMENT PLANS • BNCM • Jul 29, 2024 9:00 AM
Glidelogic Corp. Announces Revolutionary AI-Generated Content Copyright Protection Solution • GDLG • Jul 26, 2024 12:30 PM